Lumbar intervertebral disc degeneration associated with low back pain (containing lumbar disc herniation)
Conditions
Interventions
Take NAC (300 mg / tablet) 2 tablets plus take 1 placebo tablet, total 3 tablets once 3 times a day for 24 weeks
Take NAC (300 mg / tablet) 3 tablets once 3 times a day for 24 weeks
Take 3 placebo tab
Sponsors
Keio University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All participants who agree with enrollment in this study and meet all the criteria as bellows; 1) Lumbar intervertebral disc degeneration (Phirrmann grade : 3, 4) or lumbar disc herniation in whom VAS score is over 5.0 point. 2) Regardless of patients with hospitalized or outpatinet. 3) Regardless of disease with primary or recurrence. 4) Agreement to stop anti-inflammatory analgesic except for an approved medicine.
Exclusion criteria
Exclusion criteria: 1) Severe combined complications of heart, liver and blood diseases. 2) Patients with surgical treatment that attending physician consider having impact on the results. 3) Three times higher of AST/ALT before administration of NAC 4) Currently taking NAC or supplement containing NAC. 5) Allergy for NAC 6) Women who are during pregnancy, under lactation, have a possibility to pregnancy, and who hope pregnancy. 7) Previous spine surgery 8) Incompetent patients judged by attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantitative assessment of disc degeneration using Q-space imaging. | — |
Countries
Japan
Contacts
Public ContactWatanabe Kota
Keio University School of Medicine Department of Orthopaedic Surgery
Outcome results
None listed